

02/15/02
JCA U.S. PTO

02-19-02

PTO/SB/05 (11-06)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

A/Box
S/2Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	A080 US
First Inventor	Browning
Title	BAFF RECEPTOR (BCMA), An...
Express Mail Label No.	EL475127425US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. Applicant claims small entity status.
See 37 CFR 1.27.
3. Specification [Total Pages 41]
(preferred arrangement set forth below)
 - Descriptive title of the invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. Drawing(s) (35 U.S.C. 113) [Total Sheets 19]
5. Oath or Declaration [Total Pages]
- a. Newly executed (original or copy)
b. Copy from a prior application (37 CFR 1.63 (d))
(for continuation/divisional with Box 18 completed)
- i. **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. Application Data Sheet. See 37 CFR 1.76

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

 Continuation Divisional Continuation-in-part (CIP)

of prior application No. PCT/US00/22507

Prior application information: Examiner _____

Group Art Unit _____

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

<input type="checkbox"/> Customer Number or Bar Code Label	(Insert Customer No. or Attach Bar code label here)			<input type="checkbox"/> or <input type="checkbox"/> Correspondence address below
Name	Timothy P. Linkkila			
	BIOGEN, INC.			
Address	14 Cambridge Center			
City	Cambridge	State	MA	Zip Code
Country	USA	Telephone	(617) 679-3795	Fax (617) 679-2838
Name (Print/Type)	Timothy P. Linkkila	Registration No. (Attorney/Agent)	40,702	
Signature	Timothy P. Linkkila		Date	2/15/02

Burden Hour Statement This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231

JC929 U.S. PRO
10/07/02

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$ 1,430)

Complete if Known

Application Number	
Filing Date	
First Named Inventor	Browning
Examiner Name	
Group Art Unit	
Attorney Docket No.	A080 US

METHOD OF PAYMENT

1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number	02-2327
Deposit Account Name	

Charge Any Additional Fee Required
Under 37 CFR 1.16 and 1.17
 Applicant claims small entity status.
See 37 CFR 1.27

2. Payment Enclosed:

Check Credit card Money Order Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Small Entity

Fee Code (\$)	Fee (\$)	Fee Code (\$)	Fee Description	Fee Paid
101	740	201	370	Utility filing fee
106	330	206	165	Design filing fee
107	510	207	255	Plant filing fee
108	740	208	370	Reissue filing fee
114	160	214	80	Provisional filing fee
SUBTOTAL (1) (\$)				740

2. EXTRA CLAIM FEES

Total Claims	21	-20** =	1	X	18	=	18	Fee from below	Fee Paid
Independent Claims	11	- 3** =	8	X	84	=	672		
Multiple Dependent							0		

Large Entity Small Entity

Fee Code (\$)	Fee (\$)	Fee Code (\$)	Fee Description
103	18	203	9
102	84	202	42
104	280	204	140
109	84	209	42
110	18	210	9
SUBTOTAL (2) (\$)			

*or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
105	130	205	65 Surcharge - late filing fee or oath
127	50	227	25 Surcharge - late provisional filing fee or cover sheet
139	130	139	130 Non-English specification
147	2,520	147	2,520 For filing a request for ex parte reexamination
112	920*	112	920* Requesting publication of SIR prior to Examiner action
113	1,840*	113	1,840* Requesting publication of SIR after Examiner action
115	110	215	55 Extension for reply within first month
116	400	216	200 Extension for reply within second month
117	920	217	460 Extension for reply within third month
118	1,440	218	720 Extension for reply within fourth month
128	1,960	228	980 Extension for reply within fifth month
119	320	219	160 Notice of Appeal
120	320	220	160 Filing a brief in support of an appeal
121	280	221	140 Request for oral hearing
138	1,510	138	1,510 Petition to institute a public use proceeding
140	110	240	55 Petition to revive - unavoidable
141	1,280	241	640 Petition to revive - unintentional
142	1,280	242	640 Utility issue fee (or reissue)
143	460	243	230 Design issue fee
144	620	244	310 Plant issue fee
122	130	122	130 Petitions to the Commissioner
123	50	123	50 Processing fee under 37 CFR 1.17(q)
126	180	126	180 Submission of Information Disclosure Stmt
581	40	581	40 Recording each patent assignment per property (times number of properties)
146	740	246	370 Filing a submission after final rejection (37 CFR § 1.129(a))
149	740	249	370 For each additional invention to be examined (37 CFR § 1.129(b))
179	740	279	370 Request for Continued Examination (RCE)
169	900	169	900 Request for expedited examination of a design application

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid **SUBTOTAL (3) (\$)** 0

SUBMITTED BY

Complete if applicable

Name (Print/Type)	Timothy P. Linkkila	Registration No. (Attorney/Agent)	40,702	Telephone	(617) 679-3795
Signature	<i>Timothy P. Linkkila</i>	Date	<i>2/5/02</i>		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Docket No. A080 US

Applicant: Browning, et al.

Serial No.: Not Assigned yet

Filing Date: Herewith

For: Baff Receptor (BCMA), An Immunoregulatory Agent

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence:

Utility Patent Application Transmittal, Fee Transmittal, Statement regarding Sequence Listing, Paper and Electronic copies of Sequence, Utility Application (41 pages) and 19 sheets of drawings, authorization to charge our deposit account


is being deposited with the United States Postal Service under 37 CFR 1.10 as Express Mail Label No. EL475127425US in an envelope addressed to:

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

on February 15, 2002.

Date

Patricia Hofstetter



Docket No. A080 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Browning, et al.
Serial No.: Not assigned yet
Filing Date: Herewith
For: Baff Receptor (BCMA), An Immunoregulatory Agent

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Post Office via Express Mail Label EL475127425US addressed to BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Date: February 15, 2002

Signature: 

STATEMENT REGARDING SEQUENCE LISTING


Applicant hereby submits a diskette containing a machine-readable copy of the Sequence Listing done in FastSEQ 4.0.

The contents of the paper and computer readable copies are the same and, include no new matter, as required by 37 C.F.R. 1.821 (e). The sequences on the diskette and on the paper listing are identical to the sequences submitted in the application as filed.

Please charge our deposit account 02-2327 for any deficiencies.

Respectfully submitted,

Date: 2/15/02


Timothy P. Linkila
Reg. No. 40,702
BIOGEN, INC.
14 Cambridge Center
Cambridge, MA 02142
(617) 679-3795

#9553